Ono Pharmaceutical Co., Ltd. · TSE:4528
Ono Pharmaceutical — 44th Annual J.P. Morgan Healthcare Conference (January 2026)
30 slides from Ono Pharmaceutical's conference presentation, Jan 14, 2026
Slide 1: 44th Annual J.P. Morgan Healthcare Conference
44th Annual J.P. Morgan Healthcare Conference January 14, 2026
Slide 2: Introduction
Introduction Corporate Overview Key for Future Growth • Life Cycle Management of OPDIVO • Impact of Deciphera Acquisition • Valuable Products from Deciphera • Acceleration of Pipeline Development Outlook for the Future Toichi Takino, Ph.D. Representative Director, 1 President and Chief Operating Off
Slide 3: Forward-Looking Statements
Forward-Looking Statements Forecasts and other forward-looking statements included in this document are based on information currently available and certain assumptions that the Company deems reasonable. Actual performance and other results may differ significantly due to various factors. Such facto
Slide 4: Corporate Overview
Corporate Overview ono
Slide 5: ONO's History of Over 300 Years
ONO’s History of Over 300 Years For patients worldwide : 1717 2014 Toward becoming “Global Specialty Pharma” Established in World’s first launch Doshomachi, anti-PD-1 antibody Osaka, Japan “OPDIVO” 1968 2024 Acquired Deciphera (US) Started direct sales in the US and Europe World’s first company to a
Slide 6: Innovation Focus and Open Innovation
Innovation Focus and Open Innovation As of October 30, 2025 Focus Area Immunology & Oncology Inflammation Neurology Partners South Korea 5
Slide 7: Revenue Growth over the Past 15 Years
Revenue Growth over the Past 15 Years FY2025 Revenue 600 490 JPY bn （JPY bn） (Forecast) 500 400 300 Anti PD-1 antibody Acquisition of Deciphera 200 OPDIVO launch (June 2024) 100 0 2011 2012 2013 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 (Fiscal Year) 6
Slide 8: ONO Today
ONO Today 売上高 Life Cycle Management of OPDIVO Driving Global Growth Deciphera with Deciphera • Loss of Exclusivity 9% (US, International) • QINLOCK (Launched) － US : 2028 － EU : 2030 • ROMVIMZA (Approved) ONO (KR, TW) － JP : 2031 Royalties and Others 3% － US (Feb 2025) 33% － EU (Sep 2025) • New Form
Slide 9: Key for Future Growth
Key for Future Growth Life Cycle Management of OPDIVO Impact of Deciphera Acquisition Valuable Products from Deciphera Acceleration of Pipeline Development
Slide 10: Strategic LCM Initiatives in Progress
Life Cycle Management of OPDIVO : Strategic LCM Initiatives in Progress OPDIVO Sales in JP (JPY bn) Approved Indications Price Revision Melanoma 2014 142.3 145.5 (Forecast) NSCLC 2015 120.3 120.0 RCC 2016 Others 112.4 103.9 98.8 Hodgkin’s lymphoma 2016 GC 90.1 90.6 UC 87.3 Head and Neck Cancer 2017
Slide 11: Impact of Deciphera Acquisition
Impact of Deciphera Acquisition
Slide 12: Further beyond OPDIVO: Driving Growth with Deciphera
Further beyond OPDIVO : Driving Growth with Deciphera Acquisition completed in June 2024 and P/L consolidation started in July 2024 1 Product + 1 Late-Stage Program* Pipeline Enrichment US / EU Platform for Clinical Development, Geographical Expansion Registration and Commercialization Strengthening
Slide 13: Successful Integration with Deciphera
Successful Integration with Deciphera Geographic Expansion with Complementary Coverage ONO Deciphera Headquarters Osaka Waltham, Massachusetts Reinforcement of Pipeline • QINLOCK Sales Growth • Sapablursen (ONO-0530) Global In-Licensed • ROMVIMZA Launch • Early-Stage Pipeline (DCC-3009 etc.) Leverag
Slide 14: Valuable Products from Deciphera
Valuable Products from Deciphera
Slide 15: QINLOCK (Ripretinib)
(Ripretinib) Characteristic QINLOCK is the only approved drug for 4th line Product Positioning GIST in the US, Europe and others Mechanism of KIT Inhibitor / Small molecule (Oral) 1st Line 2nd Line 3rd Line 4th Line Action Imatinib Sunitinib Regorafenib QINLOCK® • GIST 4th line : Approved (US 2020,
Slide 16: ROMVIMZA (Vimseltinib)
(Vimseltinib) ROMVIMZA has the potential to be Product Positioning Characteristic best-in-class CSF1R inhibitor for TGCT in the US and Europe Surgery Recurrence Systemic Mechanism of Treatment CSF1R Inhibitor / Small molecule (Oral) Diagnosis Action ROMVIMZA Not amenable to surgery • TGCT : Approved
Slide 17: Vimseltinib MOTION Phase 3 Trial 2-Year Data
Vimseltinib MOTION Phase 3 Trial 2-Year Data Week 25 ≥2 years on studyb Efficacy Vimseltinib Placebo Vimseltinib Crossover n = 83 n = 40 n = 83 n = 35 At 2 years, Vimseltinib demonstrated a RECIST v1.1 durable antitumor efficacy consistent with ORR, n (%) 33 (40%)a 0 40 (48%) 19 (54%) the results at
Slide 18: Acceleration of Pipeline Development
Acceleration of Pipeline Development
Slide 19: Our Pipeline
Our Pipeline As of October 30, 2025 Phase 1 - Phase 2 Pivotal Filing・Approval ONO-8250 Inlexisertib / DCC-3116 QINLOCK QINLOCK HER2-expressing solid tumor・P1 Advanced malignancies・P1/2 GIST2L, KIT Exon 11+17/18・P3 GIST4L・Approved in >40 counries ONO-4685 DCC-3009 Tirabrutinib / ONO-4059 BRAFTOVI T-c
Slide 20: Pipeline Progress (FY2024-2026)
Pipeline Progress (FY2024-2026) As of October 30, 2025 FY2024 FY2025 FY2026 QINLOCK ROMVIMZA ONO-4578 Tirabrutinib / ONO-4059 GIST4L TGCT GC・P2 PCNSL ROMVIMZA OPDIVO ONO-2808 Cenobamate / ONO-2017 MSI-High CRC MSA・P2 Epilepsy TGCT HCC OPDIVO Povetacicept / ONO-8531 Sapablursen / ONO-0530 ONO-2020 UC
Slide 21: Tirabrutinib (ONO-4059)
Tirabrutinib (ONO-4059) Tirabrutinib is the first drug approved in PROSPECT : Primary Endpoint: ORR by IRC Japan (VELEXBRU) for the treatment of ORR by IRC Characteristic PCNSL. There are currently no approved n (%) 95% CI treatments for PCNSL in the US ORR (CR+CRu+PR) 32 (67%) 52, 80 Mechanism of B
Slide 22: Sapablursen (ONO-0530)
Sapablursen (ONO-0530) IMPRSSION : Phase 2a, Multicenter, Randomized, Open-Label Trial Sapablursen (ONO-0530) increases hepcidin production by suppressing the TMPRSS6 of Sapablursen in Patients With Phlebotomy-Dependent PV Characteristic gene expression, thereby reducing red blood Screening Treatmen
Slide 23: ONO-2808
ONO-2808 ONO-2808 is expected to reduce the Movement disorder Wheelchair accumulation of aberrant α-synuclein in Assisted walking Bedridden Death Characteristic oligodendrocytes or neurons, contributing Autonomic dysfunction mobility to the protection of the myelin sheath Mechanism of Sphingosine 1-
Slide 24: ONO-4578
ONO-4578 ONO-4578 is expected to have an antitumor activity Phase 1 Characteristic by abolishing the immunosuppressive mechanism mediated by the binding of PGE2 to the EP4 receptor Both the M1/M2 macrophage ratio and the T cell signature score increased T-cell Gene Signature and M1/M2 Macrophage Gen
Slide 25: Launch Projections (-FY2031)
Launch Projections (-FY2031) Solid Tumor Nivolumab sc Japan CRC 1L UC, Neoadjuvant, Adjuvant BRAFTOVI OPDIVO (ONO-4538HSC) MSI-H/dMMR CRC 1L HCC Adjuvant IgAN OPDIVO/YERVOY OPDIVO Povetacicept (ONO-8531) HCC 1L Epilepsy OA OPDIVO/YERVOY Cenobamate (ONO-2017) Gel-One (ONO-5532) FY2024 FY2025 FY2026 F
Slide 26: Outlook for the Future
Outlook for the Future ono
Slide 27: Prospect for the Next 10 Years
Prospect for the Next 10 Years Growth Driver Global QINLOCK (GIST) ROMVIMZA (TGCT) Tirabrutinib (PCNSL) Global sales Sapablursen (Polycythemia Vera) Japan sales ONO-4578 (Gastric Cancer) (other than OPDIVO) ONO-2808 (MSA) etc. Japan Povetacicept Royalties Cenobamate, Gel-One® etc. Japan sales Nivolu
Slide 28: Capital Allocation (FY2022-2026)
Capital Allocation (FY2022-2026) Planned as of Apr 2022 Assumption for FY2025-2026 Result of FY2022-2024 Update (as of May 2025) ≈ 300 JPY bn R&D R&D • Cumulative annual expenses for ≈ 600 JPY bn 2 years ≈ 350 JPY bn ≈ 100 JPY bn Strategic Investments Strategic investments • M&A ≈ 250 JPY bn • Pipel
Slide 29: ONO's Philosophy
ONO’s Philosophy Dedicated to the Fight against Disease and Pain
Slide 30: Dedicated to the Fight against Disease and Pain
Dedicated to the Fight against Disease and Pain For further information, please contact: Ono Pharmaceutical Co., Ltd. Investor Relations Email: public_relations@ono-pharma.com
Ono Pharmaceutical — 44th Annual J.P. Morgan Healthcare Conference (January 2026) on 6ix